HA-1 T-cell receptor T cells

**HA-1 T-cell receptor T cells** is a target-specific descriptor rather than a single uniquely named drug product. It refers to investigational T-cell receptor engineered T-cell therapies in which donor-derived or autologous T cells are genetically modified to express a T-cell receptor recognizing the hematopoiesis-restricted minor histocompatibility antigen HA-1H presented by HLA-A*02:01. The intended mechanism is selective elimination of recipient-derived hematopoietic and leukemic cells after allogeneic hematopoietic cell transplantation while limiting damage to nonhematopoietic tissues and reducing the risk of graft-versus-host disease. Clinical-stage versions have been evaluated in phase 1 studies for relapsed, persistent, refractory, or recurrent acute leukemia and other hematologic malignancies after allogeneic transplantation. The earlier Leiden strategy used retrovirally transduced donor-derived CMV- or EBV-specific T cells; this specific manufacturing approach showed acceptable infusion safety but insufficient feasibility and efficacy for continued development in that form.

Other names

HA-1 TCR-T cellsHA1 TCR-T cellsHA 1 TCR-T cellsHA-1H TCR-T cellsHA1H TCR-T cellsHA 1H TCR-T cellsHA-1 T TCR T cellsHA1 T TCR T cellsHA 1 T TCR T cellsHA-1H T-cell receptor transduced T cellsHA1H T-cell receptor transduced T cellsHA 1H T-cell receptor transduced T cells